115450 On Other Exchanges
Symbol
Exchange
KOSDAQ

g-treebnt co ltd (115450) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for G-TREEBNT CO LTD (115450)
\

Related News

No related news articles were found.

g-treebnt co ltd (115450) Related Businessweek News

No Related Businessweek News Found

g-treebnt co ltd (115450) Details

G-treeBNT Co., Ltd. researches and develops pharmaceutical products in South Korea and internationally. The company is developing the GBT-201 for the treatment of ophthalmologic diseases, such as dry eye syndrome and neurotrophic keratopathy; GBT-101 for treating epidermolysis bullosa dermal disease; and OKN-007 for the treatment of glioblastoma brain cancer. It also produces pumps, motors, fan motors, and transformers. The company was formerly known as Digital Aria, Co., Ltd. and changed its name to G-treeBNT Co., Ltd. in 2014. G-treeBNT Co., Ltd. was founded in 2000 and is based in Seongnam, South Korea.

Founded in 2000

g-treebnt co ltd (115450) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

g-treebnt co ltd
G-treeBNT Co., Ltd., Annual General Meeting, Mar 29, 2019

G-treeBNT Co., Ltd., Annual General Meeting, Mar 29, 2019, at 09:00 Korea Standard Time.

RegeneRx Biopharmaceuticals, Inc. and GtreeBNT Provide Updates on Clinical Trials

RegeneRx Biopharmaceuticals, Inc. announced a clinical trial update provided by GtreeBNT, RegeneRx's partner for development of RGN-259 and RGN-137 in the U.S. Regarding progress on ARISE-3, the manufacturing of the investigational product for ARISE-3 has been completed and the protocol for the study has been finalized and is now ready for the study. Also, since funding for the ARISE-3 clinical study is progressing smoothly towards the final stage, The company will do their best to inform the customer of ARISE-3 study initiation as soon as possible. The company also hope that their potential discussions with multinational pharmaceutical companies for a deal will accelerate the process by launching the ARISE-3 clinical trial. ARISE-3 is the designation for the phase 3 clinical trial for RGN-259, RegeneRx's sterile, preservative-free, eyedrop to treat dry eye syndrome and other corneal wound disorders. The production of investigational product for an Open Study has been completed. The company also have a signed a contract with the clinical sites where recruitment of EB patients will start soon. In terms of the regulatory aspect, the FDA already approved the company's open study protocol. The company are currently preparing for the final clinical trial with the goal of FPFV (first patient first visit) to occur in November 2018. In June of this year, the U.S. FDA has announced new guidelines solely for EB, and The company is currently revising the company study design for Phase 3 in accordance with the new FDA guidelines. The company is preparing to enter the clinical trial phase 3 in 2019. The company's open study which is starting now is expected to make a decisive contribution to setting up a strategic clinical phase 3 study incorporating the new U.S. FDA guidelines. The EB clinical trial is to test RGN-137, RegeneRx's dermal gel for wound healing in epidermolysis bullosa patients. EB is an orphan disease in the U.S. and EU.

GtreeBNT Enters Joint Venture with YuYang DNU to Develop RGN-137 for Treatment of Epidermolysis Bullosa

RegeneRx Biopharmaceuticals Inc. announced that GtreeBNT, has entered into a joint venture with YuYang DNU to develop RGN-137 on a global basis for the orphan indication, epidermolysis bullosa (EB). The joint venture between the two companies is Lenus Therapeutics, LLC (Lenus), a GtreeBNT U.S. subsidiary. Gtree will contribute the intellectual property rights and all development results for RGN-137 and YuYang will invest about $17.8 million in cash into Lenus. Lenus is first planning to conduct an open study to attract big pharma, which has expressed ongoing interest in the product. The Phase 3 trial is then expected to enroll approximately 200 subjects around the world, including in the U.S. EB is a rare genetic disease that most often appears in the skin, although it can also affect internal organs. There are currently no medications approved for the treatment of EB. RGN-137, a topical gel initially developed by RegeneRx Biopharmaceuticals Inc.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

115450 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 115450.
View Industry Companies
 

Industry Analysis

115450

Industry Average

Valuation 115450 Industry Range
Price/Earnings 100.0x
Price/Sales 12.9x
Price/Book 9.3x
Price/Cash Flow 167.7x
TEV/Sales 11.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact G-TREEBNT CO LTD, please visit www.gtreebnt.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.